Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2025 Jul 3;6(7):1295. doi: 10.1038/s43018-025-01026-w

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

Wen Lei 1,2,#, Hui Liu 1,#, Wenhai Deng 3,#, Wei Chen 4,#, Yun Liang 1, Wenxia Gao 4, Xianggui Yuan 1, Shanshan Guo 1, Ping Li 5, Jinyong Wang 6, Xiangmin Tong 7,✉, Yi Eve Sun 4,✉, Aibin Liang 5,✉, Wenbin Qian 1,2,✉
PMCID: PMC12296552  PMID: 40610723

Correction to: Nature Cancer 10.1038/s43018-025-00940-3, published online 18 April 2025.

In the version of the article initially published, due to an error in figure assembly, the sixth mouse in the “19 CAR-NK” (Day 2) images in Fig. 1d was a duplicate of the second mouse in the same group. Additionally, the “18.2 CAR-NK” (Day 37) mouse image was a duplicate of the sixth “18.2 CAR-NK” (Day 30) mouse directly above it. The amended figure with the correct images is now available in the HTML and PDF versions of the article.

Contributor Information

Xiangmin Tong, Email: tongxiangmin@163.com.

Yi Eve Sun, Email: yi.eve.sun@gmail.com.

Aibin Liang, Email: lab7182@tongji.edu.cn.

Wenbin Qian, Email: qianwb@zju.edu.cn.


Articles from Nature Cancer are provided here courtesy of Nature Publishing Group

RESOURCES